0QN1.LSE Santhera Pharmaceuticals Holding AG

Healthcare Commercial Services & Supplies London Exchange
31.30 GBP
Close of Nov 3, 2026
10.16 18.72
Market cap
GBP 201M
P/E
-
P/B
-
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.

Is 0QN1.LSE undervalued?

Graham number

The Graham number of Santhera Pharmaceuticals Holding AG cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Santhera Pharmaceuticals Holding AG fundamental analysis

No fundamental analysis for Santhera Pharmaceuticals Holding AG yet.

Santhera Pharmaceuticals Holding AG stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Santhera Pharmaceuticals Holding AG

Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and sells medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia. The company's lead pipeline candidate includes Vamorolone, which is developed for the treatments of Duchenne muscular dystrophy. Santhera Pharmaceuticals Holding AG was founded in 2004 and is based in Pratteln, Switzerland.

Full company profile